Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Ziftomenib Added to NCCN Clinical Practice Guidelines for NPM1-Mutant R/R AML

November 26th 2025

The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.

FDA Grants Priority Review to Sonrotoclax for R/R Mantle Cell Lymphoma

November 26th 2025

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Evolving Approaches With BTK Inhibition and Targeted Therapy Seek to Improve Outcomes in High-Risk MCL

November 26th 2025

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma

November 25th 2025

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

ctDNA Insights Stand at the Forefront of Data-Driven, Individualized MIBC Management

November 25th 2025

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Dr Freedland on the Efficacy Results From the EMBARK Trial of Enzalutamide in Prostate Cancer

November 24th 2025

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases

November 23rd 2025

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma

November 23rd 2025

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG

November 23rd 2025

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma

November 22nd 2025

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma

November 22nd 2025

Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

CELMoDs Aim to Build on Established IMiDs in Multiple Myeloma Management

November 21st 2025

Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

November 21st 2025

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Dr Bellmunt on Efficacy Findings With ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 19th 2025

Joaquim Bellmunt, MD, PhD, discusses the efficacy data seen with ctDNA-guided adjuvant atezolizumab in MIBC.

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

November 18th 2025

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

FDA Approves Epcoritamab for R/R Follicular Lymphoma

November 18th 2025

The FDA approved epcoritamab plus rituximab and lenalidomide for relapsed or refractory follicular lymphoma indications.

Neladalkib Proves Effective in TKI-Pretreated, Advanced ALK+ NSCLC

November 17th 2025

Neladalkib elicited responses and was active in the CNS in TKI-pretreated patients with advanced ALK-positive NSCLC, including lorlatinib-naive patients.

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma

November 17th 2025

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.